Can pharmacogenetics help smokers quit?

Pharmacogenomics

Volumn 7, Issue 8, 2006, Pages 1137-1140

  Munafo, Marcus ^a   Lerman, Caryn ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; DOPAMINE 2 RECEPTOR; DRUG METABOLIZING ENZYME; NICOTINE; NORTRIPTYLINE; PLACEBO; RIMONABANT; VARENICLINE; VENLAFAXINE;

CIGARETTE SMOKING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG METABOLISM; DRUG RESPONSE; DRUG TOLERANCE; EDITORIAL; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; NEUROIMAGING; NICOTINE REPLACEMENT THERAPY; PHARMACOGENETICS; PUBLIC HEALTH; SMOKING CESSATION PROGRAM; SUSTAINED RELEASE PREPARATION; TOBACCO DEPENDENCE; UNSPECIFIED SIDE EFFECT;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; HUMANS; METABOLIC DETOXICATION, DRUG; NICOTINE; PHARMACOGENETICS; SMOKING; SMOKING CESSATION;

EID: 33845887483     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.7.8.1137     Document Type: Editorial

References (27)

1. Doll R, Peto R, Boreham J, Sutherland I: Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 328, 1519 (2004).
2. Hughes JR: Motivating and helping smokers to stop smoking. J. Gen. Intern. Med. 18, 1053-1057 (2003).
3. Munafò MR, Lerman C, Niaura R, Shields AE, Swan GE: Smoking cessation treatment: pharmacogenetic assessment. Curr. Opin. Mol. Ther. 7, 202-208 (2005).
4. Munafò MR, Shields AE, Berrettini WH, Patterson F, Lerman C: Pharmacogenetics and nicotine addiction treatment. Pharmacogenomics 6, 211-223 (2005).
5. Lerman C, Jepson C, Wileyto EP et al.: Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology 3l, 231-242 (2006).
6. Lerman C, Wileyto EP, Patterson F et al.: The functional μ opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J. 4, 184-192 (2004).
7. Munafò MR, Johnstone EC, Wileyto EP, Shields PG, Elliot KM, Lerman C: Lack of association of 5-HTTLPR genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiol. Biomarkers Prev. 15, 398-400 (2006).
8. Johnstone EC, Yudkin PL, Hey K et al.: Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 14, 83-90 (2004).
9. Yudkin P, Munafò M, Hey K et al.: Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial. BMJ 328, 989-990 (2004).
10. Berrettini WH, Wileyto EP, Epstein L et al.: Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. Biol. Psychiatry (2006) (In press).
11. Lerman C, Shields PG, Wileyto EP, et al.: Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol. 22, 541-548 (2003).
12. David SP, Brown RA, Papandonatos GD et al.: Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob. Res. (2006) (In press).
13. Swan GE, Valdes AM, Ring HZ et al.: Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenomics J. 5, 21-29 (2005).
14. Cinciripini P, Wetter D, Tomlinson G et al.: The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood. Nicotine Tob. Res. 6, 229-239 (2004).
15. Boyadjieva NI, Sarkar DK: The secretory response of hypothalamic β-endorphin neurons to acute and chronic nicotine treatments and following nicotine withdrawal. Life Sci. 61, PL59-PL66 (1997).
16. Robinson TE, Berridge KC: The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res. Rev. 18, 247-291 (1993).
17. Lerman C, Shields PG, Wileyto EP et al.: Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics 12, 627-634 (2002).
18. Lerman C, Tyndale R, Patterson F et al.: Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin. Pharmacol. Ther. 79, 600-608 (2006).
19. Malaiyandi V, Lerman C, Benowitz NL, Jepson C, Patterson F, Tyndale RF: Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol. Psychiatry 11, 400-409 (2006).
20. Dahl JP, Jepson C, Levenson R et al.: Interaction between variation in the D2 dopamine receptor (DRD2) and the neuronal calcium sensor-1 (FREQ) genes in predicting response to nicotine replacement therapy for tobacco dependence. Pharmacogenomics J. 6, 194-199 (2006).
21. Neville MJ, Johnstone EC, Walton RT: Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum. Mutat. 23, 540-545 (2004).
22. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG: Replication validity of genetic association studies. Nat. Genet. 29, 306-309 (2001).
23. Liu QR, Drgon T, Walther D et al.: Pooled association genome scanning: validation and use to identify addiction vulnerability loci in two samples. Proc. Natl Acad. Sci. USA 102, 11864-11869 (2005).
24. David SP, Munafò MR, Johansen-Berg H et al.: Ventral striatum/ nucleus accumbens activation to smoking-related pictorial cues in smokers and nonsmokers: a functional magnetic resonance imaging study. Biol. Psychiatry 58, 488-494 (2005).
25. Munafò M, Mogg K, Roberts S, Bradley BP, Murphy M: Selective processing of smoking-related cues in current smokers, ex-smokers and never-smokers on the modified Stroop task. J. Psychopharmacol. 17, 310-316 (2003).
26. Ray R, Jepson C, Patterson F et al.: Association of OPRM1 A118G variant with the relative reinforcing value of nicotine. Psychopharmacology (Berl) 188, 355-363 (2006).
27. Woolacott NF, Jones L, Forbes CA et al.: The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technol. Assess. 6, 1-245 (2002).